Welcome to our dedicated page for EBR Systems SEC filings (Ticker: EBRCZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EBR Systems's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EBR Systems's regulatory disclosures and financial reporting.
EBR Systems, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on director elections and multiple equity compensation items. The meeting will be held online on May 7, 2026 (Australia) / May 6, 2026 (U.S.), with a record date of March 9, 2026.
Proposals include electing two Class II directors, approving an increase of 18,010,366 shares of Common Stock reserved under the 2021 Equity Incentive Plan via its 4% “evergreen” feature, and approving option grants to the CEO and other directors. If approved, the plan’s base share reserve would rise to 54,849,798 shares, with ASX Exception 13 treatment.
The proxy details how holders of Common Stock and CHESS Depositary Interests can vote or instruct CHESS Depositary Nominees, quorum and vote thresholds, ASX voting exclusions, and board/committee composition. It also notes a previously approved but not yet implemented reverse stock split in a range of 1-for-5 to 1-for-20, which would proportionately adjust share and CDI amounts when effected.
EBR Systems, Inc. President and CEO John McCutcheon exercised stock options to acquire 109,100 shares of common stock at an exercise price of $0.55 per share. The transaction converted previously granted options into directly held shares, with no open-market sale reported. Following the exercise, 109,100 common shares are shown as directly owned, and the related option grant originally covered 1,590,000 shares, vesting monthly beginning on June 29, 2024.
EBR Systems, Inc. is a U.S.-based medical device company focused on the WiSE CRT System, a leadless cardiac resynchronization therapy platform that paces the left ventricle using ultrasound energy instead of traditional leads.
On April 11, 2025, the FDA’s Center for Devices and Radiological Health approved the company’s premarket approval application for WiSE CRT for specific adult heart failure patients who need CRT but cannot receive or are high risk for conventional coronary sinus leads. As a condition of approval, EBR must run a long-term post-approval study following implanted patients for up to five years.
U.S. reimbursement is bolstered by CMS programs: WiSE received New Technology Add-On Payment and Transitional Pass-Through status starting October 1, 2025, with NTAP covering up to $41,145 per case based on an average selling price of $63,300. EBR is executing a phased U.S. commercial rollout, from soft launch to a Limited Market Release and planned full market release in the second half of 2026, while preparing for future launches in Australia, the U.K. and EU.
The company holds an extensive patent and trademark portfolio around WiSE CRT, but faces risks including dependence on single-source components, stringent global regulatory obligations, extensive post-market commitments, evolving reimbursement and healthcare reform, cybersecurity exposure, and the need to scale manufacturing, sales, and specialized talent to support growth.
EBR Systems, Inc. is asking stockholders to vote at a virtual Annual Meeting on May 7, 2026 (Australia) / May 6, 2026 (U.S.). The meeting agenda includes election of two directors and nine proposals, notably Proposal 2 to add 18,010,366 shares to the 2021 Equity Incentive Plan by operation of its “evergreen” provision. As of the record date, there were 450,435,794 shares outstanding. The Board has approved, but not yet implemented, a reverse stock split (ratios between 1-for-5 and 1-for-20) that will change CDI transmutation if effected prior to final adjustments. Proxy materials and the 2025 Form 10-K are available at the Company’s investor center.
EBR Systems, Inc. reported that stockholders approved all three proposals at a virtual special meeting held on March 11, 2026. Investors authorized a reverse stock split of the company’s common stock at a ratio between 1-for-5 and 1-for-20, to be implemented at the board’s discretion, with 233,231,110 votes in favor and 970,364 against.
Stockholders also ratified the prior issuance of 55,900,000 CHESS Depositary Interests (equivalent to 55,900,000 common shares) at an issue price of A$1.00 per CDI under ASX Listing Rule 7.4, and approved a potential adjournment of the meeting if additional proxy solicitations had been needed.
EBR Systems, Inc. director Will R. Allan reported exercising stock options into common shares. On February 26, 2026, he exercised options covering 58,500 shares at an exercise price of $0.16 per share, receiving the same number of common shares.
Following this transaction, Allan also reports indirect ownership of common stock through related parties, including 5,937,224 shares held by the Allan Will U/A DT 6/14/2012 and 600,000 shares held by family member Taphne Ann Lux. The filing notes these holdings represent common stock underlying Chess Depositary Interests traded on the Australian Securities Exchange.
EBR Systems, Inc. is calling a virtual special meeting of stockholders to approve several corporate actions, led by a reverse stock split of its common stock. The Board is seeking authority to implement a reverse split at any whole-number ratio between 1‑for‑5 and 1‑for‑20, at its discretion, while keeping total authorized common shares at 600,000,000. This would sharply reduce the 450,259,169 shares of common stock currently outstanding and increase the pool of authorized but unissued shares, supporting potential future equity or debt financings. CHESS Depositary Interests (CDIs) will not be consolidated; instead, the CDI‑to‑share ratio will change to match the chosen split ratio, with no expected change in the underlying value per CDI.
Stockholders are also being asked to ratify the prior issuance of 55,900,000 CDIs at A$1.00 each under a 2025 institutional placement that helped raise approximately A$75.9 million to fund commercialization of the WiSE® CRT system, manufacturing scale‑up, sales expansion, R&D, and working capital. Approval would restore capacity under ASX Listing Rule 7.1 for additional future issuances. A third proposal would allow adjournment of the meeting, if needed, to solicit more proxies. The Board unanimously recommends voting “FOR” all three proposals.
EBR Systems, Inc. is asking stockholders at a virtual special meeting to approve a reverse stock split, ratify prior securities issuances, and allow a potential adjournment to gather more votes. The reverse split would combine between 5 and 20 existing shares into 1 new share, with the exact ratio set later by the Board, and would not reduce the 600,000,000 authorized common shares. CHESS Depositary Interests will not be consolidated; instead, the CDI-to-share ratio will change so each CDI continues to reflect the same underlying value after the split.
Because the split reduces shares outstanding without changing authorized shares, the number of authorized but unissued shares would rise, giving the company more flexibility to issue equity in future financings. Stockholders are also asked to ratify the prior issue of 55,900,000 CDIs at A$1.00 each under a 2025 institutional placement so those securities are excluded from the 15% ASX Listing Rule 7.1 limit. As of the record date, 450,259,169 common shares (including CDIs) were outstanding and entitled to vote.
EBR Systems, Inc. filed a current report to share that it has issued a press release describing its commercial and clinical progress and preliminary financial results for the fourth quarter and full year ended December 31, 2025. The company noted that the press release, dated January 12, 2026, includes early estimates only, which are unaudited and may change once normal closing and audit procedures are completed.
The press release, titled “EBR Announces Strong Q4 FY 2025 Commercial and Clinical Progress,” is furnished as an exhibit and is not deemed filed for liability purposes under securities laws, nor automatically incorporated into other securities filings unless specifically referenced.
EBR Systems, Inc. reported Q3 2025 results as it begins commercial rollout of its WiSE CRT System following FDA approval on April 11, 2025. Revenue reached $512,093, generating gross profit of $223,722. Operating expenses were $12.1 million (R&D $6.24 million; SG&A $5.86 million), resulting in an operating loss of $11.88 million and a net loss of $12.19 million for the quarter. For the nine months, revenue was $681,797 with a net loss of $34.71 million.
As of September 30, 2025, cash, cash equivalents and marketable securities totaled $70.40 million, including cash and equivalents of $12.64 million and short-term marketable securities of $55.72 million. Notes payable, net, were $40.73 million with maturity in 2027. Inventory increased to $11.17 million as production scaled. Stockholders’ equity was $38.65 million. Shares outstanding were 449,889,450 as of September 30, 2025; the company reported 449,994,658 outstanding as of November 12, 2025.